Lung Cancer PBMC

About Lung Cancer PBMC

Lung Cancer PBMC for Tumour Immunology and Immuno-Oncology Research

Lung Cancer PBMC samples are isolated from the peripheral blood of IRB-consented donors with a clinically confirmed lung cancer diagnosis, cryopreserved in CryoStor® CS10 and processed within 24 hours of collection. These peripheral blood mononuclear cells give access to the systemic immune compartment of lung cancer patients — the population that determines checkpoint inhibitor response and the one most amenable to serial and pre/post-treatment sampling.

Systemic Tumour Immunology in Lung Cancer

Lung cancer is a neoplastic disease driven by accumulated somatic alterations in respiratory epithelium, and it is one of the tumour types where immunotherapy has most reshaped treatment. The circulating immune compartment in these patients is measurably altered, and those alterations are the substrate of most immuno-oncology biomarker work.

• Non-small cell lung cancer and small cell lung cancer differ substantially in biology and immune responsiveness, and NSCLC is further divided into adenocarcinoma and squamous cell histologies with distinct molecular profiles.
• PD-L1 expression and tumour mutational burden are the established predictive contexts for immune checkpoint blockade in NSCLC, and their systemic immune correlates are studied directly in PBMC.
• Circulating T cells in lung cancer patients show altered activation and inhibitory receptor expression, including PD-1, TIM-3 and LAG-3, supporting exhaustion-focused phenotyping and functional rescue assays.
• Regulatory T cells and myeloid-derived suppressor cells are expanded in the circulation of many lung cancer patients and can be quantified and functionally tested from cryopreserved PBMC.
• Smoking-associated mutational burden generates a substantial neoantigen load, and tumour-reactive T cells can be interrogated by peptide stimulation, cytokine capture and TCR sequencing.
• Actionable driver alterations including EGFR, ALK, ROS1 and KRAS segregate with different immune phenotypes and treatment pathways, making molecularly annotated donors valuable.

Donor Stratification Available

• Histology: adenocarcinoma, squamous cell carcinoma, or small cell lung cancer where documented
• Stage at collection: early-stage, locally advanced, or metastatic
• Driver mutation status where documented (EGFR, ALK, ROS1, KRAS and others)
• PD-L1 expression status where documented
• Treatment status: treatment-naive, on chemotherapy, on targeted therapy, on immune checkpoint inhibitor, or post-resection
• Smoking history: current, former, or never-smoker
• Treatment response category where documented
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed lung cancer donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• Viability and recovery reported per lot
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified lung cancer diagnosis, histology and stage where documented
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Treatment history, current regimen and smoking history where documented
• Self-reported allergies and infectious disease history
• Additional lung cancer-specific data available upon request

Applications

• Immunophenotyping of circulating T, B, NK and myeloid populations
• Immune checkpoint expression profiling and blockade response assays
• T cell exhaustion and activation state characterisation
• Regulatory T cell and myeloid suppressor cell quantification and function
• Tumour antigen-specific T cell detection and TCR repertoire sequencing
• Single-cell RNA sequencing of the systemic immune compartment
• CAR-T, T cell engager and cell therapy target validation and potency testing
• Immunotherapy response biomarker discovery and validation

Other Lung Cancer Specimen Types

• Lung Cancer Plasma
• Lung Cancer Serum
• Lung Cancer Whole Blood
• Lung Cancer Leukopak
• Non Small Cell Lung Cancer PBMC
• Lung Adenocarcinoma Whole Blood

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent system
• HIPAA-compliant donor data protection
• Documentation support available for regulatory review

Ordering & Customization

Lung Cancer PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, international orders or regulatory documentation, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our full PBMC inventory, visit our human PBMC page.